Top 5 Income Companies To Own For 2015

In august, the Association of Equipment Manufacturers (AEM) published the mid-year review for the agricultural sector. Their findings point to a slowdown for the industry, highlighting a 9.5% decline on exports through the first half of 2013. Also, late soybean planting in the USA is expected to compound the industry’s slowdown. So, what are the prospects for AGCO (AGCO), CNH Global (CNH), and Deere & Co. (DE) under such conditions?

Size, efficiency, diversity

CNH is the smallest of the three, and continues to grow international presence. For example, the firm bought 25% of India’s TAFE, graving an important share of the tractors market. Additionally, returns in capital continue to improve through a business strategy based on internal profitability and working capital investments.

Future growth for AGCO remains in the international arena, in the Asian region specifically. Because, sale volumes in the US, South America, and Europe are expected to dwin dle after five years of continued increments.

Top 5 Income Companies To Own For 2015: Premiere Opportunities Group Inc (PPBL)

Premiere Opportunities Group, Inc., formerly Premiere Publishing Group, Inc., incorporated on March 25, 2005, was a magazine publishing company. The Company’s primary objective is to identify an operating company with a view to achieving long-term growth.

The Company had operated principally through two wholly owned subsidiaries Sobe Life LLC and Poker Life LLC. The Company has discontinued all publishing activities. As of December 31, 2011, it had not generated any revenues.

Advisors’ Opinion:

  • [By Jonathan Yates]

    For investors, there are three reasons to be bullish about luxury item stocks, ranging from well-known brands such as Ralph Lauren (NYSE: RL) and Coach (NYSE: COH), to promising small caps like Premier Opportunities Group (OTC: PPBL).

Top 5 Income Companies To Own For 2015: Interleukin Genetics Inc (ILIU.PK)

Interleukin Genetics, Inc., incorporated on March 28, 2000, is a personalized health company, which develops genetic tests to provide information to manage health and specific health risks. The Company’s business focuses on personalized health, by providing genetic tests with clinical value. Its tests are made available through marketing partners or directly to end users. The Company’s primary business focus and strategy is to continue the Company’s commercialization efforts with its PST genetic test. In addition, the Company plans to continue to develop and sells tests for its own business needs under the Inherent Health brand.

The Company’s genetic tests that are being commercialized includes PST is a genetic test, which analyzes genetic variations associated with inflammation and identifies individuals who are at increased risk for more severe periodontal disease; Weight Management Genetic Test determines whether a low fat, low carbohydrate or balanced di et may normal or vigorous exercise, which is needed to lose existing body fat; Bone Health Genetic Test is designed to identify whether an individual is more likely to be susceptible to spine fractures and low bone mineral density associated with osteoporosis; Heart Health Genetic Test is designed to identify genetic predisposition to excess inflammation, which is a risk factor for heart attack, and Wellness Select Genetic Test allows buyers to purchase any combination of Inherent Health genetic tests at a discounted price. The Company is also focusing its genetic test development efforts on the development of an Osteoarthritis, or OA, genetic test to identify individuals at increased risk for severe OA.

Genetic Test for Risk of Periodontal Disease

PST is a genetic test that analyzes genetic variations associated with inflammation and identifies individuals who are at increased risk for more severe periodontal disease. The PST genetic test identifi es specific polymorphisms (genetic variations) in genes that! regulate the production of interleukin cytokines.Interleukin-1 (IL-1) is well-established as one of the critical regulators of periodontal disease, and studies in non-human primates have shown that drugs specifically blocking IL-1 alone or IL-1 plus TNFa reduces tissue destruction even when the bacterial challenge is not reduced.

Inherent Health Brand of Genetic Tests

The Company’s Weight Management Genetic Test helps take the guesswork out of finding an effective diet and exercise solution by revealing actionable steps to achieve weight goals based on genetics. The test provides new information beyond traditional assessments, so that nutritional intake and fitness routines can be tailored for improved, sustainable results. This test identifies five SNPs in four human genes: fatty acid binding protein 2 (FABP2); adrenergic receptor beta 2 (ADRB2 two variations); adrenergic receptor beta 3 (ADRB3); and peroxisome proliferator-activated receptor gamm a (PPAR- ). These markers are involved in certain physiological pathways relating to body weight. Certain patterns of markers are associated with differential response to certain diet and exercise regimens.

The Company has conducted a number of studies that demonstrate a gene-diet interaction based on the multi-locus patterns . In the original study, 311 overweight/obese (body mass index, 27-40 kg/m2), nondiabetic, premenopausal, generally healthy women were randomly assigned for 12 months to either the Atkins-like ( low carbohydrate), Zone-like (low carbohydrate), LEARN-like (balanced), or Ornish-like (low fat) diets for the primary purpose of losing weight. The data collected in that study included dietary intake assessment (three unannounced 24-hour recalls for each time point administered by a dietitian and analyzed using NDS-R, University of Minnesota), anthropometric measures including weight, and related physiological variables, all collected at baseline, two, six, and 12 months.

Bone Health Genetic T! est

The Company’s Bone Health Genetic Test is designed to identify whether an individual is more likely to be susceptible to spine fractures and low bone mineral density associated with osteoporosis. Although it typically starts later in life, early intervention can help prevent osteoporosis. Preventive measures can reduce the risk for bone loss and fractures, which in the case of vertebral fractures leads to a hunched over appearance. The test identifies a SNP in each of three genes involved in processes that affect bone; estrogen receptor alpha (ER1 Xba1), vitamin D receptor (VDR), and interleukin-1 (IL-1). Certain patterns of variations are associated with increased risk of spine fracture and/or low bone mineral density. The test can be used as an aid to making diet, exercise, and other lifestyle choices to maintain and improve bone health.

Nutritional Needs Genetics Test

The Company’s Nutritional Needs Genetics Test is designed to identify DNA variations in genes crucial to B-vitamin metabolism and the ability to manage oxidative stress. Individuals with certain variations in these genes may be at increased risk for ineffective utilization of B-vitamins and potential for cell damage caused by oxidative stress, both of which can in some cases lead to increased risk for certain diseases. The test identifies the presence or absence of human genotypic markers methylenetetrahydrofolate reductase (MTHFR) and transcobalamin II (TCN2) involved in vitamin B metabolism and markers superoxide dismutase 2 (SOD2), glutathione S-transferase 1 deletions (GSTM1), paraoxonase 1 (PON1), X-ray repair cross complementing group 1 (XRCC1) in response to oxidative stress. Certain variations are associated with less efficient B-vitamin metabolism or reduced activity of endogenous anti-oxidant systems. The test may be used to aid individuals in deciding whether to supplement their diet with B vitamins and/or antioxidants.

< p>Genetic Test Pipeline

The Company is focusing! its gene! tic test development efforts on programs, including Osteoarthritis Genetic Test. OA is the common adult joint disease, increasing in frequency and severity in all aging populations. The estimated U.S. prevalence is 20-40 million patients or five times that of rheumatoid arthritis. The Company’s OA program plans to investigate whether interleukin gene variations together with several other inflammatory gene variations is associated with the occurrence of multi-joint OA for the development of a genetic risk assessment test.

Advisors’ Opinion:

  • [By Brian Marckx]

    Interleukin Genetics, Inc. (ILIU.PK) develops genetic tests focused on personal health. Through applied genetics research and scientific collaborations, the company has made significant progress in understanding how genetic make-up can affect an individual’s predisposition and risk of suffering from certain diseases. Interleukin’s research has specifically focused on a form of genetic variation called single nucleotide polymorphisms (SNP) and how it can have an impact on a person’s health. The company has applied this knowledge in the development of genetic tests focused on areas such as weight management, cardiovascular health and periodontal disease. Interleukin sells its Inherent Health line of tests, which launched in 2009, to the consumer market and maintains a CLIA-certified lab at its headquarters in Waltham, Massachusetts, where consumers send test samples for processing.

Top 5 Income Companies To Own For 2015: Direxion Daily Semiconductor Bull 3X Shares (SOXL)

Direxion Daily Semiconductor Bull 3x Shares (the Fund) seeks daily investment results of 300% of the price performance of the PHLX Semiconductor Sector Index (Semiconductor Index). The Semiconductor Index measures the performance of the semiconductor subsector of the United States equity market. Component companies are engaged in the design, distribution, manufacture and sale of semiconductors. As of February 18, 2010, the Semiconductor Index included companies with capitalizations between $1.7 billion and $114 billion. The distributor of the Fund is Foreside Fund Services, LLC. Advisors’ Opinion:

  • [By John Udovich]

    On Thursday after the market closed, mid cap fabless semiconductor stock Marvell Technology Group Ltd (NASDAQ: MRVL) reported earnings and was slipping in after hours trading, meaning its worth taking a closer look at those earnings along with the performance of potential semiconductor benchmarks like the SPDR S&P Semiconductor ETF (NYSEARCA: XSD), iShares PHLX SOX Semiconductor Sector (NASDAQ: SOXX) and Direxion Daily Semiconductor Bull 3X Shares (NYSEARCA: SOXL). In case you aren’t familiar with the term fabless semiconductor, it’s a business model that involves the outsourcing the manufacturing of silicon wafers. Most semiconductor companies are actually fabless because of the high cost of building a facility and manufacturing fab. Therefore, fabless semiconductor companies can concentrate on the design and marketing of chips while outsourcing the actual production to larger foundry companies.

  • [By John Udovich]

    There appears to be light at the end of the tunnel for mid cap fabless semiconductor stock Marvell Technology Group Ltd (NASDAQ: MRVL) despite the fact that the company has lost a patent infringement battle with Carnegie Mellon University that could cost it $1.54 billion, meaning its worth taking a closer look at the stock along with the performance of semiconductor ETF benchmarks like SPDR S&P Semiconductor ETF (NYSEARCA: XSD), iShares PHLX SOX Semiconductor Sector (NASDAQ: SOXX) and Direxion Daily Semiconductor Bull 3X Shares (NYSEARCA: SOXL).

Top 5 Income Companies To Own For 2015: KBR Inc. (KBR)

KBR, Inc. operates as an engineering, construction, and services company supporting the energy, hydrocarbon, government services, minerals, civil infrastructure, power, and industrial sectors worldwide. Its Downstream business unit provides front end engineering design; detailed engineering; engineering, procurement, and construction (EPC); EPC management; and program management services to petrochemical, refining, coal gasification, and syngas markets. The company?s Government and Infrastructure business unit provides program and project management, contingency logistics, operations and maintenance, construction management, engineering, and other services to military and civilian branches of governments and private clients. Its Services business unit delivers engineering, construction, construction management, fabrication, maintenance, and turnaround services. It also offers maintenance, construction, and drilling support services for offshore oil and gas producing facili ties using semisubmersible vessels. This segment serves oil, gas, petrochemicals, and hydrocarbon processing industries, as well as power, alternate energy, pulp and paper, industrial and manufacturing, and pharmaceutical industries. The company?s Technology business unit offers various process technologies, including value-added technologies in the coal monetization, petrochemical, refining, and syngas markets. Its Upstream business unit constructs liquefied natural gas, gas-to-liquids, onshore oil and gas production facilities, offshore oil and gas production facilities, and onshore and offshore pipelines. The company?s Ventures business unit invests in and manages projects, where the company provides engineering, construction, construction management or operations, and maintenance services. KBR, Inc. was founded in 1901 and is based in Houston, Texas.

Advisors’ Opinion:

  • [By Lisa Levin]

    KBR (NYSE: KBR) shares fell 1.16% to touch a new 52-week low of $23.95 after UBS downgraded the stock from Buy to Neutral.

    AEP Industries (NASDAQ: AEPI) shares touched a new 52-week low of $34.20. AEP shares have dropped 56.11% over the past 52 weeks, while the S&P 500 index has gained 15.91% in the same period.

  • [By Aaron Levitt]

    Those hefty contract wins, plus the forward P/E of just 14 — make CBI one of the best stocks to buy.

    KBR (KBR)

    Spun-off from oil service stock Halliburton (HAL), KBR (KBR) could an interesting “value” pick for building outAmerica’s energy boom.

Top 5 Income Companies To Own For 2015: Thermo Fisher Scientific Inc(TMO)

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacture, analysis, discovery, and diagnostics. Its Analytical Technologies segment offers analytical instruments to analyze prepared samples, software interpretation tools, laboratory information management systems, and laboratory automation systems; environmental instruments and integrated systems for environmental monitoring, safety, and security applications; and process instruments, integrated systems, and measurement solutions. It also provides diagnostics products used in healthcare laboratories to prepare and analyze patient samples; and biosciences products comprising reagents and consumables used in life science research, drug discovery, and biopharmaceutical production. The company?s Laboratory Products and Services segment offers laboratory equipment, including sample preparation, environment storage and handling equipment, and laboratory workstations; laboratory consumables; research market solutions consisting of chemicals, instruments and apparatus, liquid handling pumps and devices, and capital equipment and consumables; and healthcare market products comprising analytical equipment, diagnostic tools, and reagents and consumables. It also provides workplace and first responder equipment, protective gear, and apparel; and packaging, warehousing, distribution, labeling, pharmaceutical and biospecimen storage, and analytical laboratory services in the area of drug discovery and pharmaceutical clinical trials. The company serves pharmaceutical and biotechnology companies, hospitals and clinical diagnostic labs, universities, research institutions, government agencies, and environmental and industrial process control settings primarily in the United States, Germany, and the United Kingdom. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Advisors’ Opinion:

  • [By Victor Selva]

    As we can see, the firm has a lower ROE than Abbott Laboratories (ABT), Thermo Fisher Scientific Inc. (TMO) and CVS Caremark Corporation (CVS).

    Final Comment

  • [By gurujx]

    Thermo Fisher Scientific Inc (TMO): Sr. VP & CFO Peter M Wilver sold 91,897 Shares

    Sr. VP & CFO Peter M Wilver sold 91,897 shares of TMO stock on Feb. at the average price of $115.21. Peter M Wilver owns at least 104,305 shares after this. The price of the stock has increased by 2.22% since.

  • [By Tess Stynes]

    General Electric Co.’s(GE) healthcare unit agreed to acquire several of Thermo Fisher Scientific Inc.’s(TMO) life-sciences businesses for roughly $1.06 billion.